Subscribe here to receive future editions. Happy Friday! Buried in the election news this week was new data from drugmakers ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

While I’ve read some mixed opinions, it appears his win is seen as modestly positive for the pharmaceutical industry, including AstraZeneca. For one, his administration is likely to be more ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

GlobalData is the parent company of Clinical Trials Arena. Amgen and AstraZeneca are also investigating Tezspire in other ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Stay in the know with a recap of our top stories today. 1. AstraZeneca to open new $2b facility in Tuas by 2029, promises 800 ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

The global oral solid dosage pharmaceutical formulation market is poised for remarkable expansion, with projections indicating a growth from USD 629,582.6 million in 2024 to USD 895,636.0 million by ...